JHSM
Journal of Health Sciences and Medicine

Journal of Health Sciences and Medicine (JHSM) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

ISSN: Active
eISSN: 2636-8579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
A biomarker predicting unfavorable prognosis in malignant pleural mesothelioma: systemic immune–inflammation index
Abstract
Aims: Malignant pleural mesothelioma (MPM) is an extremely mortal condition. Only a few prognostic biomarkers have been described for MPM. Our study looked into the association between patient survival and the Systemic Immune Inflammation Index (SII). Material and
Methods: A total of 158 patients who were admitted to our hospital between January 2013 and December 2022, and had a histopathologically confirmed diagnosis of MPM were included in the study. Before treatment, hematological parameters and SII were determined. A Spearman's correlation analysis was performed to analyze the correlation of mean survival with hematological parameters.
Results: The study involved 158 patients in all. 70 patients had a history of smoking, the median age was 63 years, the mean survival time was 15.3 months, and 57.6% of the participants were men. The epithelioid type (84.2%) was the most prevalent histological subtype, and 29 patients had stage 4 illnesses. Of the participants, 84% had received chemotherapy, and 22% had received radiotherapy before. Among the 39 patients who had surgery, 5 had an extrapleural pneumonectomy. SII mean±sd was (1427.2±1207.3). The patients with stage 4 disease had significantly shorter survival (p=0.001). The patients who had surgery survived significantly longer (p=0.01). Hemoglobin (Hb) (r:0.21, p:0.01) and Hematocrit (Hct) (r:0.18, p:0.03) values showed weak positive correlations with mean survival. It was evident that mean survival got shorter as SII (r:-0.17, p:0.04) and neutrophil-lymphocyte ratio (NLR) (r:-0.19, p:0.02) values got higher. On the other hand, there was a strong positive association between mean survival and the lymphocyte-monocyte ratio (LMR) (r:0.21, p:0.01). When the parameters that had statistically significant differences among the groups were taken as control variables and the statistical analysis was re-performed, it was found that Hgb and Hct values as well as NLR and LMR ratios lost their significant correlations with survival. However, the SII ratio was still negatively correlated with survival (r:-0.16, p:0.04).
Conclusion: Pretreatment SII is a noninvasive and easy-to-calculate biomarker that predicts the prognosis of MPM. It is negatively correlated with mean survival regardless of the tumor stage and surgical management.

Keywords : Malignant pleural mesothelioma, systemic immune-inflammation index, prognosis, survival

Download Article


1. Cao S, Jin S, Cao J, et al. Malignant pericardial mesothelioma: asystematic review of current practice. Herz 2018; 43: 61-8.
2. Zhang A, Cao S, Jin S, et al. Elevated aspartate aminotransferaseand monocyte counts predict unfavorable prognosis in patientswith malignant pleural mesothelioma. Neoplasma 2017; 64: 114-22.
3. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleuralmesothelioma. J Clin Oncol2009; 27: 2081-90.
4. Geltner C, Errhalt P, Baumgartner B, et al. Management ofmalignant pleural mesothelioma-part 1: epidemiology, diagnosis,and staging: consensus of the Austrian Mesothelioma InterestGroup (AMIG). Wien Klin Wochensch 2016; 128: 611-7.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation,and cancer. Cell 2010; 140: 883-99.
6. Shalapour S, Karin M. Immunity, inflammation, and cancer:an eternal fight between good and evil. J Clin Invest 2015; 125:3347-55.
7. Bernhardt D, Aufderstrasse S, Konig L, et al. Impact ofinflammatory markers on survival in patients with limited diseasesmall-cell lung cancer undergoing chemoradiotherapy. CancerManag Res 2018; 10: 6563-9.
8. Cao S, Jin S, Shen J, et al. Selected patients can benefit more fromthe management of etoposide and platinum-based chemotherapyand thoracic irradiation-a retrospective analysis of 707 small celllung cancer patients. Oncotarget 2017; 8: 8657-9.
9. Gao Y, Zhang H, Li Y, Wang D, Ma Y, Chen Q. Preoperativeincreased systemic immune-inflammation index predicts poorprognosis in patients with operable non-small cell lung cancer.Clin Chim Acta 2018; 484: 272-7.
10. Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50states and the District of Columbia, United States, 2003- 2008. IntJ Occup Environ Health 2013; 19: 1-10.
11. Ai J, Stevenson JP. Current issues in malignant pleuralmesothelioma evaluation and management. Oncologist 2014; 19:975-84.
12. Kim J, Bhagwandin S, Labow DM. Malignant peritonealmesothelioma: a review. Ann Transl Med 2017; 5: 236.
13. De Perrot M, Feld R, Cho BCJ, et al. Trimodality therapy withinduction chemotherapy followed by extrapleural pneumonectomyand adjuvant high-dose hemithoracic radiation for malignantpleural mesothelioma. J Clin Oncol 2009; 27: 1413-8.
14. Ismail-Khan R, Robinson LA, Williams CC, Jr Garrett CR, BeplerG, Simon GR. Malignant pleural mesothelioma: a comprehensivereview. Cancer Control 2006; 13: 255-63.
15. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis ofthe International Association for the Study of Lung CancerMesothelioma database. J Thorac Oncol 2012; 7: 1631-9.
16. Ostan R, Lanzarini C, Pini E, et al. Inflammaging and cancer: achallenge for the Mediterranean diet. Nutrients 2015; 7: 2589-621.
17. Belcher DA, Ju JA, Baek JH, et al. The quaternary state ofpolymerized human hemoglobin regulates oxygenation of breastcancer solid tumors: A theoretical and experimental study. PLoSOne 2018; 13: e0191275.
18. Peng F, Hu D, Lin X, et al. The monocyte to red blood cell countratio is a strong predictor of postoperative survival in colorectalcancer patients: the Fujian prospective investigation of cancer(FIESTA) study. J Cancer 2017; 8: 967-75.
19. Zou ZY, Liu HL, Ning N, Li SY, Du XH, Li R. Clinical significanceof preoperative neutrophil-lymphocyte ratio and plateletlymphocyte ratio as prognostic factors for patients with colorectalcancer. Oncol Lett 2016; 11: 2241-8.
20. Grieshober L, Graw S, Barnett MJ, et al. Pre-diagnosis neutrophil-to-lymphocyte ratio and mortality in individuals who developlung cancer. Cancer Causes Control 2021; 32: 1227-36.
21. Sahın F, Aslan AF. Relationship between inflammatory andbiological markers and lung cancer. J Clin Med 2018; 7: 160.
22. Wang Y, Huang D, Xu WY, et al. Prognostic value of pretreatmentlymphocyte-to-monocyte ratio in non-small cell lung cancer: ameta-analysis. Oncol Res Treat 2019; 42: 523-31.
23. Geng Y, Shao Y, He W, et al. Prognostic role of tumor-infiltratinglymphocytes in lung cancer: a meta-analysis. Cell PhysiolBiochem 2015; 37: 1560-71.
24. Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance ofneutrophil-to-lymphocyte ratio in non-small cell lung cancer: ameta-analysis. Sci Rep 2015; 5: 12493.
25. Lin GN, Peng JW, Xiao JJ, et al. Prognostic impact of circulatingmonocytes and lymphocyte-to-monocyte ratio on previouslyuntreated metastatic non-small cell lung cancer patients receivingplatinum-based doublet. Med Oncol 2014; 31: 70.
26. Gu X, Sun S, Gao XS, et al. Prognostic value of platelet tolymphocyte ratio in non-small cell lung cancer: evidence from3,430 patients. Sci Rep 2016; 6: 23893.
27. Takada K, Takamori S, Matsubara T, et al. Clinical significance ofpreoperative inflammatory markers in non-small cell lung cancerpatients: A multicenter retrospective study. Plos one 2020; 15:e0241580.
28. Wang PX, Wang HJ, Liu JH, et al. A nomogram combining plasmafibrinogen and systemic immune-inflammation index predictssurvival in patients with resectable gastric cancer. Scientific Rep2021; 11.
29. Li J, Cao D, Huang Y, et al. The Prognostic and ClinicopathologicalSignificance of Systemic Immune-Inflammation Index in BladderCancer. Cancer. Frontiers in immunology 2022; 13.
30. Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breastcancers: a meta-analysis. World J Surg Oncol 2020; 18.1: 1-11.
31. Wang D, Hu X, Xiao L, et al. Prognostic nutritional index andsystemic immune-inflammation index predict the prognosis ofpatients with HCC. J Gastrointestin Surg 2021; 25.2: 421-7.
Article available in :
Volume 6, Issue 2, 2023
Page : 389-393
https://doi.org/10.32322/jhsm.1242687
Article Information
Received : 26 Oca 2023
Accepted : 10 Şub 2023
Published : 27 Mar 2023
Corresponding Author :

Filiz Çimen: Department of Chest Disease, Private Çankaya Life Hospital, Ankara, Turkey

[email protected]
Citation : Baykal H, Çimen F. A biomarker predicting unfavorable prognosis in malignant pleural mesothelioma: systemic immune–inflammation index. J Health Sci Med 2023; 6(2): 389-393.

Read: 108
Cited: 0
Download : 152
_Footer